This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
29 Apr 2011

US Committee Supports Merck's Hepatitis C Drug

The FDA's Antiviral Drugs Advisory Committee has voted to support the approval of Merck's Victrelis for the treatment of chronic hepatitis C.

A US advisory committee for the FDA has voted to support the approval of Merck's Victrelis (boceprevir) for the treatment of chronic hepatitis C. Victrelis is one of a new class of medicines known as hepatitis C virus protease inhibitors being evaluated by the FDA.

 

The FDA's Antiviral Drugs Advisory Committee voted 18-0 to back the drug to be used in combination with other hepatitis medicines, pegylated interferon and ribavirin, reports the Wall Street Journal.

 

Merck Research Laboratories president Peter Kim said, "The positive recommendation brings us one step closer to bringing Victrelis to men and women who need it, and reinfo

Related News